Ambit Biosciences Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2000)
Status: Acquired by Daiichi Sankyo (2014)

Organization Overview

First Clinical Trial
2007
NCT00462761
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ambit Biosciences Corporation | Interim Chief Medical Officer / Ambit Biosciences Corporation | Interim Chief Medical Officer, Ambit Biosciences Corporation | Medical Monitor, Ambit Biosciences Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 1)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Glioma (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 10